Scarica l'app Stockscreener
1.56
1.89%
-0.03
Dopo l'orario di chiusura:
1.59
0.03
+1.92%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché SONN Giù?
Forum
Previsione
Frazionamento azionario
Sonnet Biotherapeutics Holdings Inc Borsa (SONN) Ultime notizie
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Corporate UpdateOn December 17, 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, released it - Defense World
Insights into Sonnet BioTherapeutics Q4 Earnings - Benzinga
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Sonnet BioTherapeutics Slashes Operating Costs 37% in FY2024, Advances Cancer Drug Pipeline - StockTitan
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Sonnet BioTherapeutics (NASDAQ: SONN) Reports Positive Safety Data in SON-1010 Monotherapy Dose Escalation Trial - Defense World
Sonnet BioTherapeutics reports progress in cancer trial By Investing.com - Investing.com Nigeria
Sonnet BioTherapeutics reports progress in cancer trial - Investing.com India
Sonnet BioTherapeutics Announces $3.9 Million Registered - GlobeNewswire
Sonnet BioTherapeutics Secures $3.9M Strategic Financing Deal Through Mixed Securities Offering - StockTitan
Sonnet BioTherapeutics Announces Topline Safety Data - GlobeNewswire
Sonnet Bio's Cancer Drug Shows Promise: 48% Disease Control, One Patient's Tumor Shrinks 45% in Phase 1 Trial - StockTitan
Sonnet BioTherapeutics reports advances in cancer treatment drug By Investing.com - Investing.com Canada
Sonnet BioTherapeutics reports advances in cancer treatment drug - Investing.com India
Sonnet BioTherapeutics Announces Publication Detailing the - GlobeNewswire
Sonnet BioTherapeutics Unveils Breakthrough Cancer Drug Delivery System in Major Publication - StockTitan
Sonnet BioTherapeutics Holdings (STU:H3D) Financial Strengt - GuruFocus.com
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Sonnet BioTherapeutics’ $5 Million Common Stock Offering - Global Legal Chronicle
Sonnet BioTherapeutics Holdings (STU:H3D) Change In Receiva - GuruFocus.com
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewswire
Sonnet BioTherapeutics Secures Crucial Patent for Novel Cancer Immunotherapy Pipeline | SONN Stock News - StockTitan
Sonnet BioTherapeutics (NASDAQ: SONN) Announces Issuance of U.S. Patent for Novel Immunotherapeutic Drug Candidates - Defense World
Sonnet BioTherapeutics secures US patent covering two drug candidates - Pharmaceutical Technology
Sonnet BioTherapeutics secures patent for cancer drug candidates By Investing.com - Investing.com Australia
SONN stock touches 52-week high at $9.9 amid market optimism - Investing.com Australia
Sonnet BioTherapeutics Prices of $5.0 Million Underwritten Public Offering - citybiz
Sonnet BioTherapeutics Announces Pricing of $5.0 Million - GlobeNewswire
Sonnet BioTherapeutics sets $5 million stock offering - Investing.com India
Sonnet BioTherapeutics sets $5 million stock offering By Investing.com - Investing.com UK
Sonnet BioTherapeutics Raises $5M in Stock Offering with Warrant Coverage | SONN Stock News - StockTitan
Sonnet BioTherapeutics secures patent for cancer drug candidates - Investing.com India
U.S. Stock market: SONN(+86.46%), DataChat(+50.28%), Cytek Biosciences(+30.51%) among the top gainers during early trading - Business Upturn
Sonnet BioTherapeutics Secures Patent for Cancer Drugs - TipRanks
Sonnet BioTherapeutics Announces Issuance of U.S. Patent - GlobeNewswire
Sonnet BioTherapeutics Secures Key Patent for Novel Cancer Immunotherapy Drugs | SONN Stock News - StockTitan
Dow Jumps Over 1,200 Points; Donald Trump Wins White House - Benzinga
Sonnet stock tumbles 22% in wake of proposed offering filing - MSN
(SONN) On The My Stocks Page - Stock Traders Daily
When (SONN) Moves Investors should Listen - Stock Traders Daily
Sonnet BioTherapeutics (SONN) Stock Surges After Regaining Nasdaq Compliance - Stocks Telegraph
Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance - TipRanks
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq - GlobeNewswire
SONN (Sonnet BioTherapeutics Holdings) Capex-to-Operating-C - GuruFocus.com
Sonnet BioTherapeutics Enters into Licensing Agreement with Alkem Laboratories for DPN in India - Chemical Industry Digest
Alkem Labs inks pact with Sonnet BioTherapeutics to develop, commercialise drug candidate for diabetic... - Medical Dialogues
Alkem Labs partners with Sonnet BioTherapeutics to develop drug candidate for diabetic peripheral neuropathy in India - BSI bureau
Alkem Labs enters into licensing agreement with Sonnet BioTherapeutics for its diabetic peripheral neuropathy drug in India - The Financial Express
Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics - Equity Bulls
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):